This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cell & Gene Therapy Manufacturing & Commercialization US

Early Bird Savings and Poster Submission Deadline Expires In:

  • 00
  • 00
  • 00
  • 00
September 27-30, 2022
Boston Convention and Exhibition CenterBoston, MA

Alex Klarer
Director of MSAT and Acting Head of R&D at BioCentriq


Alex Klarer has a background in Chemical Engineering focused on bioprocessing and process engineering. He has held roles at Genentech and Hitachi where he led the translational process development for a range of cell therapies and ex-vivo gene therapies including T-cell immunotherapies, stem cell therapies, and MSC mediated immunoregulation. Alex also has experience developing novel technologies and applications to address gaps in manufacturing capabilities. He looks forward to continuing to partner with groundbreaking regenerative medicine companies and helping their therapies reach patients.

Agenda Sessions

  • Plenary Panel Discussion: Beyond Rare Diseases - Overcoming the Challenges of Expanding to Larger Patient Populations with Cell and Gene Therapies


Speakers at this event